Skip to main content

Table 5 Change of treatment status at time of follow-up in relation to EQ-5D

From: Responsiveness of the EuroQoL 5-Dimension (EQ-5D) questionnaire in patients with spondyloarthritis

At follow-up

 

% (n)

EQ-5D scores

Change of EQ-5D scores

p-valuea

EQ-VAS

Change of EQ-VAS

p-valuea

Baseline

Follow-up

Baseline

Follow-up

Change of treatment

Yes

13.2% (20)

0.76 (0.21)

0.75 (0.26)

-0.03 (0.13)

0.742

64.75 (19.27)

65.25 (21.18)

0.50 (17.06)

0.870

No

86.8% (131)

0.80 (0.18)

0.80 (0.17)

0.00 (0.11)

63.74 (17.85)

65.12 (17.70)

1.42 (21.10)

Change of biologics

Yes

2.6% (4)

0.71 (0.29)

0.81 (0.06)

-0.05 (0.11)

0.459

58.00 (32.29)

63.75 (24.96)

5.75 (14.57)

0.644

No

97.4% (147)

0.80 (0.18)

0.79 (0.19)

0.00 (0.11)

64.03 (17.60)

65.18 (18.01)

1.18 (20.72)

Change of NSAIDs/COX-2 Inhibitors

Yes

1.3% (2)

0.71 (0.24)

0.75 (0.28)

0.04 (0.04)

0.236

52.50 (24.75)

55.00 (21.21)

2.50 (3.54)

0.889

No

98.7% (149)

0.80 (0.18)

0.79 (0.18)

0.00 (0.11)

64.03 (17.94)

65.28 (18.12)

1.28 (20.70)

Change of DMARDs

Yes

2.0% (3)

0.81 (0.10)

0.87 (0.05)

0.10 (0.14)

0.262

66.67 (15.28)

66.67 (20.82)

0.00 (10.00)

0.835

No

98.0% (148)

0.80 (0.18)

0.79 (0.19)

-0.01 (0.11)

63.82 (18.07)

65.11 (18.14)

1.33 (20.73)

Addition of NSAIDs/COX-2 Inhibitors

Yes

2.0% (3)

0.72 (0.38)

0.59 (0.61)

-0.13 (0.23)

0.340

65.67 (13.65)

86.67 (7.64)

21.00 (8.54)

0.039*

No

98.0% (148)

0.80 (0.18)

0.80 (0.16)

0.00 (0.11)

63.84 (18.09)

64.70 (18.01)

0.90 (20.55)

Addition of DMARDs

Yes

2.0% (3)

0.90 (0.06)

0.91 (0.04)

0.03 (0.04)

0.579

78.33 (7.64)

56.67 (32.15)

-21.67 (25.66)

0.081

No

98.0% (148)

0.79 (0.18)

0.79 (0.18)

0.00 (0.11)

63.58 (18.02)

65.31 (17.87)

1.77 (20.28)

Addition of biologics

Yes

4.0% (6)

0.76 (0.14)

0.72 (0.11)

-0.05 (0.06)

0.123

66.00 (16.31)

65.83 (18.55)

-0.17 (10.68)

0.672

No

96.0% (145)

0.80 (0.18)

0.80 (0.19)

0.00 (0.12)

63.78 (18.10)

65.11 (18.17)

1.36 (20.89)

  1. NSAIDs non-steroidal anti-inflammatory drugs, COX-2 Cyclooxygenase-2; DMARDs Disease-modifying anti-rheumatic drugs (including sulphasalazine, methotrexate, leflunomide); EQ-5D EuroQol 5-dimension; EQ-VAS EuroQol visual analogue scale
  2. a Mann-Whitney U test for comparison of change of scores/VAS between Yes and No groups *denotes statistical significance p<0.05